en.globes.co.il
Cure8 news brief
Teva jumps on FDA approval for biosimilar
Medications
Ustekinumab
Biosimilars
IL-12/23 inhibitor
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Why This Matters
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and market development rather than new clinical evidence about treatment effects.
Who Should Pay Attention
Adult patients on or considering ustekinumab (Stelara), caregivers, clinicians who prescribe biologics, and people following biosimilar access and drug-cost issues.
Study Snapshot
Story typeBusiness news
Evidence typeRegulatory update
Source depthFull source text
What To Know
This is a regulatory and commercial update — an FDA interchangeability ruling means the biosimilar can be substituted for the reference biologic at the pharmacy level in the U.S., and the article highlights Teva’s launch and market implications rather than clinical data or new trial results.
For patients: Interchangeability may affect availability, insurance coverage, and potentially cost or prescribing choices in the future, but the article does not report any new efficacy or safety data specific to Selarsdi.
For clinicians/researchers: The news is relevant for formulary decisions and market competition; clinicians should consult product labeling, FDA documents, and payor policies for details on approved indications and substitution rules.
Keep In Mind
This article is a business/news report about FDA approval and Teva’s commercial launch; it does not present clinical trial results or safety data. Substitution practices, insurance coverage, and local pharmacy policies will determine how and when patients might be switched. For clinical details, refer to the FDA approval documents and product labeling.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationen.globes.co.il
Indexed viaBing News
Source typeBusiness news
PublishedMay 5, 2025, 6:09 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
FDA Approves Interchangeability Designation for Teva and Alvotech’s Stelara Biosimilar Selarsdi for Multiple Indications
An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to...